In a subgroup analysis of the SAFE trial in patients with ARDS, the relative risk of death was slightly lower in those who received albumin compared to those who received crystalloids, although this difference did not reach statistical significance [ 99 ].
← all excerpts
Fluid management strategies in critically ill patients with ARDS: a narrative review.
1
—
—